Gilead hands back some rights to key drug from Galapagos deal,

Studies in Crohn’s disease will still be run by Gilead, while Galapagos will handle trials testing filgotinib in ulcerative colitis. The companies also plan to …, Studies in Crohn’s disease will still be run by Gilead, while Galapagos will handle trials testing filgotinib in ulcerative colitis. The companies also plan to …, Read More

Scroll to Top